Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors.
Multifunctional rational drug design of protein tyrosine kinases inhibitors allows a potent drug to be utilized to treat more than one disease for greater patient benefits. Many protein tyrosine kinases (PTK), including Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), have been identified as potential drug targets to treat diverse diseases including cancer and disorders of the immune system. Here we review advances in JAK3 and BTK inhibitors and describe the therapeutic potential of these potent agents in the clinical setting.
Vassilev
Alexei O
AO
Parker Hughes Cancer Center; Parker Hughes Institute, Drug Discovery Program, Paradigm Pharmaceuticals, St. Paul, MN 55113, USA.
Tibbles
Heather E
HE
DuMez
Darin
D
Venkatachalam
Taracad K
TK
Uckun
Fatih M
FM
D000077329:Agammaglobulinaemia Tyrosine Kinase; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D016503:Drug Delivery Systems; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D053616:Janus Kinase 3; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D016377:Organ Transplantation / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human; C507933:JAK3 protein, human; D053616:Janus Kinase 3